Mirae Asset Global Investments’s Entrada Therapeutics TRDA Stock Holding History

Mirae Asset Global Investments’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8K	Sell	1,736 -261	-13%	-$2.5K	﹤0.01%	1545
2026 Q1	$25.2K	Buy	1,997 +140	+8%	+$1.6K	﹤0.01%	1406
2025 Q4	$19.1K	Buy	1,857 +386	+26%	+$3.25K	﹤0.01%	1539
2025 Q3	$8.53K	Buy	1,471 +5	+0.3%	+$29	﹤0.01%	1590
2025 Q2	$9.85K	Buy	1,466 +208	+17%	+$1.67K	﹤0.01%	1493
2025 Q1	$12K	Buy	1,258 +12	+1%	+$150	﹤0.01%	1453
2024 Q4	$21.7K	Buy	+1,246	New	+$22.6K	﹤0.01%	1413
2024 Q1	–	Sell	-10,874	Closed	-$164K	–	2646
2023 Q4	$164K	Hold	10,874	–	–	﹤0.01%	2374
2023 Q3	$172K	Hold	10,874	–	–	﹤0.01%	2342
2023 Q2	$165K	Buy	+10,874	New	+$150K	﹤0.01%	2395

Other funds holding TRDA

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Mirae Asset Global Investments's TRDA Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Entrada Therapeutics (TRDA) stake by 13% in Q2 2026, selling an estimated $2.5K and leaving 1,736 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1545.

Mirae Asset Global Investments first reported a position in TRDA in Q2 2023 and has held it in 10 quarters since. The position peaked at $172K in Q3 2023. 22 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Mirae Asset Global Investments held 1,736 shares of Entrada Therapeutics worth $12.8K as of Q2 2026.
Mirae Asset Global Investments sold 261 Entrada Therapeutics shares in Q2 2026, an estimated $2.5K.
Entrada Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1545 holding.
Mirae Asset Global Investments first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 10 quarters since.
Mirae Asset Global Investments's Entrada Therapeutics position peaked at $172K in Q3 2023.
22 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.